Exosomal miRNA-92a derived from cancer-associated fibroblasts promote invasion and metastasis in breast cancer by...

Prior research has shown that Cancer-associated Fibroblasts (CAFs) function as integral components of the tumor microenvironment, actively driving oncogenic progression across diverse human malignancies through complex paracrine signaling pathways. These specialized stromal cells modulate the surrounding extracellular matrix and neighboring malignant cells through the continuous secretion of extracellular vesicles, specifically exosomes, which encapsulate diverse bioactive molecules like MicroRNA (miRNA). Within the context of mammary carcinoma, these vesicles facilitate critical intercellular communication, yet the specific molecular cargo responsible for enhancing the metastatic potential of tumor cells remains only partially characterized. Previous investigations established that stromal-derived signals can trigger the Epithelial-Mesenchymal Transition (EMT), a biological process where epithelial cells lose their polarity and acquire highly invasive mesenchymal characteristics. While the general involvement of stromal fibroblasts in tumor growth is well-recognized, the precise epigenetic mechanisms linking exosomal transport to specific intracellular signaling cascades in recipient cells are not fully elucidated. This absence of evidence motivated the current investigation into how specific fibroblastic miRNAs influence the invasive phenotype and systemic dissemination of mammary carcinoma cells.

This investigation characterizes the role of exosomal MicroRNA-92a (miR-92a) derived from Cancer-associated Fibroblasts (CAFs) in driving the invasive and metastatic behavior of human breast cancer cell lines. The researchers sought to determine if these stromal vesicles transport functional genetic material to malignant cells to modulate their aggressive phenotype and facilitate escape from the primary tumor site. A primary objective involved identifying the direct intracellular targets of miR-92a, specifically Ras GTPase-activating protein-binding protein 2 (G3BP2), which may facilitate cellular migration and structural remodeling of the cytoskeleton. The study also aimed to elucidate the protein-mediated mechanisms, involving Small Nuclear Ribonucleoprotein Polypeptide A (SNRPA), responsible for the selective loading and transfer of this specific miRNA from fibroblasts. Investigators examined how the suppression of target proteins by exosomal cargo influences the nuclear translocation of transcription factors like Twist Family BHLH Transcription Factor 1 (TWIST1) associated with mesenchymal transition. Finally, the work evaluated the potential of this exosomal signaling axis to serve as a diagnostic or prognostic biomarker for identifying advanced disease stages in clinical settings.

The experimental design integrated both in vitro cellular assays and in vivo murine models to evaluate the biological impact of exosomal signaling on breast cancer progression and systemic metastasis. Researchers isolated exosomes from the conditioned media of Cancer-associated Fibroblasts (CAFs) using ultracentrifugation and characterized their molecular content using specialized nanoparticle tracking analysis and molecular biology techniques. Quantitative assessments of MicroRNA-92a (miR-92a) levels were performed using Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) to compare the cargo of stromal-derived vesicles against normal fibroblast populations. To confirm direct genetic interactions, the team utilized dual-luciferase reporter assays and Western blotting to monitor the expression levels of Ras GTPase-activating protein-binding protein 2 (G3BP2) in recipient cells. The role of Small Nuclear Ribonucleoprotein Polypeptide A (SNRPA) in the transport process was investigated through targeted genetic knockdown and overexpression experiments followed by exosomal RNA quantification. Metastatic potential was quantified in vivo by monitoring tumor dissemination and secondary growth in mice following the systemic or local administration of specific exosomal fractions derived from fibroblasts.

Experimental data revealed that Cancer-associated Fibroblasts (CAFs) significantly upregulate the secretion of MicroRNA-92a (miR-92a) within exosomes compared to the levels observed in normal, non-activated fibroblast populations. The study demonstrated that these vesicles successfully deliver functional miR-92a to breast cancer cells, where the miRNA directly targets and suppresses the expression of Ras GTPase-activating protein-binding protein 2 (G3BP2). This downregulation of the target protein triggers the release of Twist Family BHLH Transcription Factor 1 (TWIST1) from its cytoplasmic constraints, allowing its rapid translocation into the nucleus. Increased nuclear presence of this transcription factor subsequently activates the Epithelial-Mesenchymal Transition (EMT) program, markedly enhancing the migratory capacity and invasive potential of the malignant cells. The researchers identified that the RNA-binding protein Small Nuclear Ribonucleoprotein Polypeptide A (SNRPA) is essential for the efficient loading and stabilization of miR-92a into the fibroblastic exosomes. In vivo observations confirmed that the administration of CAF-derived exosomal miR-92a promotes extensive tumor invasion and systemic metastasis in mouse models, validating the findings from the cellular assays.

The findings establish a novel signaling axis where stromal-derived exosomal MicroRNA-92a (miR-92a) acts as a potent driver of breast cancer progression through the modulation of the tumor microenvironment. By identifying Ras GTPase-activating protein-binding protein 2 (G3BP2) as a critical regulator of this pathway, this research provides a mechanistic explanation for fibroblast-mediated tumor aggressiveness and metastatic spread. The discovery that Small Nuclear Ribonucleoprotein Polypeptide A (SNRPA) facilitates this transfer suggests new molecular targets for therapeutic intervention aimed at disrupting the communication between stroma and tumor. These results imply that targeting the exosomal transport of specific miRNAs could potentially inhibit the Epithelial-Mesenchymal Transition (EMT) and subsequent colonization of distant organs by malignant cells. The authors suggest that elevated levels of miR-92a in circulating exosomes may serve as a valuable non-invasive biomarker for monitoring breast cancer metastasis and predicting patient outcomes. Future studies might focus on disrupting the interaction between fibroblastic vesicles and malignant cells to improve clinical outcomes for patients suffering from highly invasive and metastatic mammary carcinomas.